PPARA and cardiovascular disorder: The dual PPARα/γ agonist aleglitazar increase adiponectin, reduce hepatic fat accumulation, augment circulating angiogenic cell migration and enhance neoangiogenesis, thus markedly reduce formation of atherosclerotic plaques and prevent the happening of the cardiovascular disease in mice experiments (21).